DRI Healthcare Trust (TSE:DHT.UN) Reaches New 12-Month High - Here's What Happened

Key Points

• DRI Healthcare Trust's shares reached a new 52-week high of C$15.21, with the stock last traded at C$15.20.
• The company announced a quarterly dividend of $0.10, representing a 2.7% yield, with a high dividend payout ratio of 528.57%.
• DRI Healthcare Trust focuses on managing a diversified portfolio of pharmaceutical royalties to capitalize on the growth in the global pharmaceuticals and biotechnology markets.

Shares of DRI Healthcare Trust (TSE:DHT.UN - ) reached a new 52-week high on Monday . The stock traded as high as C$15.21 and last traded at C$15.20, with a volume of 9775 shares traded. The stock had previously closed at C$15.05.

DRI Healthcare Trust Stock Down 0.7%

The company's 50-day moving average is C$14.49 and its two-hundred day moving average is C$13.23. The company has a market capitalization of C$829.74 million, a P/E ratio of 213.57 and a beta of 0.13.

DRI Healthcare Trust Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 20th. Investors of record on Monday, October 20th will be given a $0.10 dividend. This represents a $0.40 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, September 29th. DRI Healthcare Trust's dividend payout ratio is 528.57%.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.